RT Journal Article
SR Electronic
T1 Verification of the Abbott Alinity m Resp-4-Plex Assay for detection of SARS-CoV-2, influenza A/B, and respiratory syncytial virus
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2021.04.22.21255133
DO 10.1101/2021.04.22.21255133
A1 Cheng, Annie
A1 Riedel, Stefan
A1 Arnaout, Ramy
A1 Kirby, James E.
YR 2021
UL http://medrxiv.org/content/early/2021/04/22/2021.04.22.21255133.abstract
AB COVID-19 symptomology may overlap with other circulating respiratory viruses that may also cause severe disease and for which there are specific and potentially life-saving treatments. The Abbott Alinity m Resp-4-Plex assay is a multiplex PCR assay that simultaneously detects and differentiates infection with SARS-CoV-2, influenza A, influenza B, and respiratory syncytial virus (RSV). We characterized its accuracy, precision, and analytical sensitivity. All were found to be robust for measures examined. In the context of sample-to-answer, near random access automation on the Alinity m platform, we believe that the Resp-4-Plex assay offers significant utility in addressing the current needs of the SARS-CoV-2 pandemic and future needs during anticipated endemic circulation of SARS-CoV-2 with other respiratory viruses.Competing Interest StatementWe thank the Abbott Molecular Group for providing test reagents and LGC SeraCare control material for this work under a COVID-19 Diagnostics Evaluation Agreement. RA was a recipient of grant support from Abbott Molecular under a clinical study agreement.Funding StatementWe thank the Abbott Molecular Group for providing test reagents and LGC SeraCare control material for this work under a COVID-19 Diagnostics Evaluation Agreement. RA was a recipient of grant support from Abbott Molecular under a clinical study agreement.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The study was performed as part of normal quality assurance/quality improvement (QI) activities in our clinical laboratory. The BIDMC IRB reviewed the proposed activity and determined that the study does not constitute human subjects research as stated in its determination letter.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data is available in manuscript and supplemental data.